Ondine Biomedical, Inc.

Ondine Biomedical, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2011, Ondine Biomedical, Inc. has 9.66M shares outstanding.

As of June 30, 2011, Ondine Biomedical, Inc. maintains a current ratio of 0.41, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -138.07, indicating conservative leverage, while an interest coverage ratio of -310.10 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2011. Return on assets (ROA) is negative at -137.34, reflecting losses generated across the asset base. The company generates approximately 3.95M in revenue per employee across its workforce of 33.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.96 indicates how many times Ondine Biomedical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2011, Ondine Biomedical, Inc. recorded 64,452.38 in income tax expense. The company reported a pretax loss of -208.13M and -208.19M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Ondine Biomedical, Inc.'s stock has declined approximately 18.00% over the past 52 weeks. The 50-day moving average sits at 11.87, while the 200-day moving average is 11.65.

Over the twelve months ended June 30, 2011, Ondine Biomedical, Inc. generated 130.39M in revenue and converted that into -208.19M in net income, yielding earnings per share of -5.35. EBITDA reached -250.58M, while operating income came in at -268.31M.

As of June 30, 2011, Ondine Biomedical, Inc. holds 53.97M in cash and equivalents against 162.42M in total debt, resulting in a net debt position of 108.45M. Total book value stands at -117.64M, with working capital of -156.59M providing operational flexibility.

Ondine Biomedical, Inc. produced -196.43M in operating cash flow over the twelve months ended June 30, 2011. After subtracting -8.58M in capital expenditures, free cash flow totaled -205.01M - equivalent to -5.27 per share.

Over the twelve months ended June 30, 2011, Ondine Biomedical, Inc. posted a gross margin of 75.25, reflecting its pricing power and cost economics. The operating margin of -205.78 and net profit margin of -159.67 provide insight into operational efficiency.